Natco Pharma Ltd stock (ISIN: INE987B01026) closed at 956.55 on March 15, 2026, after a decline of 5.88%. This drop follows a period of volatility for the company’s shares, which rebounded from a low of Rs 820.35 on March 2, 2026, to around Rs 1,016 by mid-March.
The recent decline in share price has raised questions among investors, especially considering Natco Pharma’s price-to-earnings (PE) ratio of 8.00, which is significantly below the industry average of 35. This disparity suggests that the stock may be undervalued compared to its peers in the pharmaceutical sector.
In its latest quarterly results, Natco Pharma reported net sales of Rs 1,221 crore and a net profit of Rs 407 crore for the period ending March 2025. Over the past five years, the company has seen its profit after tax surge from Rs 458.10 crore to Rs 1,883.40 crore, indicating strong growth potential.
Additionally, the company maintains a healthy financial position, with a debt-to-equity ratio of -0.29, reflecting a net cash position. Natco Pharma’s return on equity stands at 24.79%, further showcasing its operational efficiency. The company’s dividend yield is currently 0.69%, with a latest payout of Rs 1.5 per share.
Natco Pharma’s stock experienced significant volatility in early March 2026, reflecting broader market sentiment around Indian equities. Investors are closely monitoring the stock’s performance as it navigates these fluctuations.
What observers say
Market analysts are divided on the future trajectory of Natco Pharma’s share price. While some believe the current valuation presents a buying opportunity, others caution that the recent decline may indicate underlying challenges. Details remain unconfirmed.
